Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

被引：8

作者：

Jazieh, A. R. ^{[1
,2
]}

Komrokji, R. ^{[1
]}

Gupta, A. ^{[1
]}

Patil, S. ^{[3
]}

Flora, D. ^{[4
]}

Knapp, M. ^{[5
]}

Issa, M. ^{[2
]}

Karim, N. Abdel ^{[1
]}

机构：

[1] Univ Cincinnati, Cincinnati, OH USA

[2] King Abdul Aziz Med City, Riyadh, Saudi Arabia

[3] Univ Memphis, Memphis, TN 38152 USA

[4] Oncol Hematol Oncol Care, Cincinnati, OH USA

[5] Mid Ohio Hematol Oncol, Columbus, OH USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 09期

关键词：

Thalidomide; non small cell lung cancer; chemotherapy; angiogenesis inhibitor; SOLID TUMORS; CHEMOTHERAPY; ANGIOGENESIS; COMBINATION; BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; PLATINUM; FUTURE;

D O I：

10.3109/07357900801944856

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study aim was to determine the efficacy and safety of the combination of Gemcitabine 1000 mg/m(2) day 1 & 8 and Irinotecan 100 mg/m(2) day 1 & 8 with escalating dose of thalidomide in chemonaive patients with advanced non-small cell lung cancer. Among the 20 patients who met eligibility criteria and received treatment, two patients (10%) experienced partial response and 14 (70%) experienced stable disease. The median time to disease progression was 4 months (95% CI: 2.8-6.6). The 1 year and 2 year survival rates were 36% and 27%, respectively. This combination is active in advanced NSCLC with manageable toxicity profile.

引用

页码：932 / 936

页数：5

共 50 条

[1] A phase II trial of thalidomide (T), irinotecan (I) and gemcitabine (G) in chemonaive patients (pts) with advanced non-small cell lung cancer (NSCLC).
Flora, DB
Kleykamp, B
Knapp, M
Shukla, R
Jazieh, AR
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 680S - 680S
[2] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer
Miller, Antonius A.
Case, Doug
Atkins, James N.
Giguere, Jeffrey K.
Bearden, James D.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) : 832 - 836
[3] Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer (NSCLC).
Miller, AA
Case, D
Atkins, J
Giguere, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 649S - 649S
[4] A phase II trial of gemcitabine and irinotecan in patients with refractory or relapsed non-small cell lung cancer.
Ohyanagi, F
Nishio, M
Horai, T
Kasahara, K
Shibata, K
Takeda, Y
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 697S - 697S
[5] Randomized phase II trial of irinotecan combined with paclitaxel or gemcitabine in untreated advanced non-small cell lung cancer
Kinoshita, A.
Fukuda, M.
Nagashima, S.
Fukuda, M.
Takatani, H.
Nakano, H.
Nakamura, Y.
Oka, M.
Soda, H.
Kohno, S.
[J]. EJC SUPPLEMENTS, 2007, 5 (04): : 382 - 382
[6] Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
Yun Fan
Neng-ming Lin
Sheng-lin Ma
Lü-hong Luo
Luo Fang
Zhi-yu Huang
Hai-feng Yu
Feng-qin Wu
[J]. Acta Pharmacologica Sinica, 2010, 31 : 746 - 752
[7] Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer
Fan, Yun
Lin, Neng-ming
Ma, Sheng-lin
Luo, Lue-hong
Fang, Luo
Huang, Zhi-yu
Yu, Hai-feng
Wu, Feng-qin
[J]. ACTA PHARMACOLOGICA SINICA, 2010, 31 (06) : 746 - 752
[8] A phase II of gemcitabine in advanced non-small cell lung cancer
Koynov, K
Tzekova, V
Mincheva, N
Scherer, A
Krejcy, K
[J]. 3RD INTERNATIONAL CONGRESS ON LUNG CANCER, 1998, : 231 - 234
[9] Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial
Masotti, A
Zannini, G
Gentile, A
Morandini, G
[J]. LUNG CANCER, 2002, 36 (01) : 99 - 103
[10] Ifosfamide and gemcitabine: A phase II trial in advanced inoperable non-small cell lung cancer
Gatzemeier, U
Manegold, C
Eberhard, W
Wilke, HJ
Chomy, F
Chomy, P
Khayat, D
Blatter, J
Seeber, S
Drings, P
[J]. SEMINARS IN ONCOLOGY, 1998, 25 (01) : 15 - 18

← 1 2 3 4 5 →